1. Survival and prognostic factors for childhood malignant liver tumors: analysis of harmonized clinical data
- Author
-
Kondilia Antoniadi, Sofia Polychronopoulou, Eleni Petridou, Helen Dana, Kalliopi Stefanaki, Evgenia Papaconstantinou, Eftichia Steiakaki, Maria A. Karalexi, Margaret Baka, Evangelia E. Ntzani, Maria Moschovi, Roman Moiseenko, Emmanuel Hatzipantelis, S.R. Varfolomeeva, Panagiota Bouka, Maria Kourti, Marina Servitzoglou, A V Filin, Denis Kachanov, Astero Malama, D.G. Akhaladze, Iordanis Pelagiadis, Katerina Strantzia, and Maria Gavra
- Subjects
Male ,Oncology ,Cancer Research ,Hepatoblastoma ,Prognostic variable ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Adolescent ,Epidemiology ,Cancer registration ,Newly diagnosed ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Humans ,In patient ,Generalizability theory ,030212 general & internal medicine ,Child ,business.industry ,Liver Neoplasms ,Infant, Newborn ,Infant ,Prognosis ,medicine.disease ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,business ,Rare disease - Abstract
Background Despite overall striking advances in survival of childhood liver tumors, outcomes remain poor for specific patient segments. We aimed to assess overall survival (OS) of this rare disease and evaluate the generalizability of prognostic variables included in international collaborative systems using, for the first time, harmonized clinical data from two geographically different cohorts (Greece and Moscow). Methods Data for children (0-14 years) with liver tumors were retrieved from two Southern-Eastern European areas (Greece; 2001-2019 and Moscow; 2012-2019). Kaplan-Meier curves were constructed, and OS values were derived from Cox proportional models controlling for study variables. Results A total of 171 newly diagnosed cases (54.4% males) were included. The OS5-year exceeded 80% in patients Conclusions Outcomes of patients with liver tumors registered in two SEE areas were comparable to those reported by major collaborative trials. Ongoing clinical cancer registration could facilitate comparison of outcomes between different study groups in order to shape state of the art of treatment.
- Published
- 2021